Article Text

Download PDFPDF
Medium-term outcomes of safe surgery system trabeculectomies
  1. J Gale1,
  2. A P Wells1,2
  1. 1
    Ophthalmology Department, Capital & Coast District Health Board, Wellington, New Zealand
  2. 2
    Capital Eye Specialists, Wellington, New Zealand
  1. Dr A P Wells, Ophthalmology Department, Wellington Hospital, Private Bag 7902, Wellington, New Zealand; twells{at}


Aim: To assess the safety and success of Safe Surgery System trabeculectomy beyond 3 years.

Methods: Consecutive case series of 39 eyes in 32 patients. Trabeculectomy was performed using fornix-based conjunctival flap, standard trabeculectomy punch, adjustable scleral flap sutures and antimetabolite treatment. Primary outcome of surgical failure was defined by two criteria: (A) need for further surgery, glaucoma medications or an intraocular pressure (IOP) >21 mm Hg during >10% of follow-up; or (B) IOP >15 mm Hg for >10% follow-up. A relatively aggressive regime of bleb needling and subconjunctival injections was used postoperatively in an attempt to reduce bleb fibrosis and failure. The mean follow-up was 42 months (range 25–55).

Results: The rate of surgical failure was 4.4% per eye-year for criterion A, and 8.0% per eye-year for criterion B. Complications were few and compared favourably with other published series.

Conclusion: The Safe Surgery System for trabeculectomy provides excellent IOP control both during the operation and in the short and medium term postoperatively, with few complications or surgical failures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This work was supported by the Capital Vision Research Trust, but we received no direct funding for this research, and cannot identify any financial competing interests.

  • Competing interests: None.

  • Ethics approval: The Central Regional Ethics Committee approved the study.

  • Patient consent: Obtained.